We have located links that may give you full text access.
Effect of hemolysis, icterus, and lipemia on three acetaminophen assays: Potential medical consequences of false positive results.
BACKGROUND: We evaluated the effect of hemolysis, icterus and lipemia on 3 acetaminophen assays: namely the Syva® EMIT®, the Microgenics DRI® assay, and the Roche assay on a Roche Cobas® c501 or an Integra 800 analyzer.
METHODS: Discarded acetaminophen - free serum samples (blank pool) and patient serum with acetaminophen overdose were used to prepare samples. Three levels of acetaminophen (5, 10, and 30 μg/ml) were evaluated for interference: hemolysis (H index range: 0-1000), icterus (I index range: 0-40), and lipemia (L index range: 0-1000).
RESULTS: Measurements showed that the EMIT® assay was not significantly affected by hemolysis or icterus at all 3concentrations evaluated, but was negatively affected by lipemia at all three levels at 1000 mg/dl intralipids. The DRI® assay was similarly affected by hemolysis and icterus, but lipemia (at 1000 mg/dl intralipids) only affected the 5 μg/ml level. The Roche acetaminophen assay was significantly affected by hemolysis at all three concentrations. It was significantly affected by icterus at 20 mg/dl bilirubin and > 5 μg/ml and at icterus levels of 30 and 40 mg/dl bilirubin at 10 and 30 μg/ml acetaminophen concentrations, respectively. However, the Roche assay was least affected by lipemia.
CONCLUSION: Hemolysis and icterus had insignificant interference on the Syva EMIT® and the DRI® assays for the analysis of acetaminophen, but significant interference effect on the Roche assay. On the other hand lipemia interfered less markedly with the Roche assay. The effect of hemolysis, icterus and lipemia should always be considered. Cautions are warranted when interpreting results for the potential false positive results in the presence of hemolysis and icterus at the concentrations evaluated in this study.
METHODS: Discarded acetaminophen - free serum samples (blank pool) and patient serum with acetaminophen overdose were used to prepare samples. Three levels of acetaminophen (5, 10, and 30 μg/ml) were evaluated for interference: hemolysis (H index range: 0-1000), icterus (I index range: 0-40), and lipemia (L index range: 0-1000).
RESULTS: Measurements showed that the EMIT® assay was not significantly affected by hemolysis or icterus at all 3concentrations evaluated, but was negatively affected by lipemia at all three levels at 1000 mg/dl intralipids. The DRI® assay was similarly affected by hemolysis and icterus, but lipemia (at 1000 mg/dl intralipids) only affected the 5 μg/ml level. The Roche acetaminophen assay was significantly affected by hemolysis at all three concentrations. It was significantly affected by icterus at 20 mg/dl bilirubin and > 5 μg/ml and at icterus levels of 30 and 40 mg/dl bilirubin at 10 and 30 μg/ml acetaminophen concentrations, respectively. However, the Roche assay was least affected by lipemia.
CONCLUSION: Hemolysis and icterus had insignificant interference on the Syva EMIT® and the DRI® assays for the analysis of acetaminophen, but significant interference effect on the Roche assay. On the other hand lipemia interfered less markedly with the Roche assay. The effect of hemolysis, icterus and lipemia should always be considered. Cautions are warranted when interpreting results for the potential false positive results in the presence of hemolysis and icterus at the concentrations evaluated in this study.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app